Results 31 to 40 of about 32,302 (223)

Potentiating TMEM16A does not stimulate airway mucus secretion or bronchial and pulmonary arterial smooth muscle contraction

open access: yesFASEB BioAdvances, 2020
The calcium‐activated chloride channel (CaCC) TMEM16A enables chloride secretion across several transporting epithelia, including in the airways. Additional roles for TMEM16A have been proposed, which include regulating mucus production and secretion and
Henry Danahay   +14 more
doaj   +1 more source

Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? [PDF]

open access: yes, 2014
The authors acknowledge the medical writing assistance received from Sam Yarwood, PhD, of Complete HealthVizion, in the form of literature searches and preparation and revision of the draft manuscript.Peer reviewedPublisher ...
Fromer, Leonard   +4 more
core   +4 more sources

Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events [PDF]

open access: yes, 2012
An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in previous Cochrane reviews.ObjectivesWe set out to compare the risks of mortality and non-fatal serious adverse events in ...
Altman   +18 more
core   +1 more source

Possibility of lipid microsphere-encapsulated Y-24180 as an injectable drug and an inhaler for the treatment of bronchoconstriction

open access: yesAllergology International, 2000
Y-241 80 ((±)-4-(2-chloro-phenyl)-2-[2-(4-isobuthyl- phenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2f][1,2,4] triazolo[4,3-a)[1,4]diazepine) is a lipophilic platelet- activating factor (PAF) antagonist.
Mitsuko Takenaga   +2 more
doaj   +1 more source

気管支喘息患者の血清コーチゾール値について. 副腎皮質ホルモン投与および年齢との関連 [PDF]

open access: yes, 1995
Serum cortisol levels were examined in 94 patients with bronchial asthma in relation to dose of glucocorticoids and age. 1. The level of serum cortisol was significantly lower in group A patients, treated with glucocorticoids (prednisolone of 5mg/day or ...
Harada, Hideo   +9 more
core   +1 more source

Regular treatment with formoterol for chronic asthma: serious adverse events [PDF]

open access: yes, 2012
Epidemiological evidence has suggested a link between beta(2)-agonists and increases in asthma mortality. There has been much debate about possible causal links for this association, and whether regular (daily) long-acting beta2-agonists are safe ...
Altman   +17 more
core   +1 more source

Review – Nutraceuticals Can Target Asthmatic Bronchoconstriction: NADPH Oxidase-Dependent Oxidative Stress, RhoA and Calcium Dynamics

open access: yesJournal of Asthma and Allergy, 2021
Mark F McCarty,1 James J DiNicolantonio,2 Aaron Lerner3 1Catalytic Longevity Foundation, San Diego, CA, USA; 2Department of Preventive Cardiology, Saint Luke’s Mid America Heart Institute, Kansas, MO, USA; 3Chaim Sheba Medical Center, The ...
McCarty MF, DiNicolantonio JJ, Lerner A
doaj  

Bronchospasm and its biophysical basis in airway smooth muscle

open access: yesRespiratory Research, 2004
Airways hyperresponsiveness is a cardinal feature of asthma but remains unexplained. In asthma, the airway smooth muscle cell is the key end-effector of bronchospasm and acute airway narrowing, but in just the past five years our understanding of the ...
Fredberg Jeffrey J
doaj   +1 more source

Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events (Review) [PDF]

open access: yes, 2009
Background Epidemiological evidence has suggested a link between beta2-agonists and increases in asthma mortality. There has been much debate about possible causal links for this association, and whether regular (daily) long-acting beta2-agonists are ...
Cates, CJ, Jaeschke, R, Lasserson, TJ
core   +1 more source

Home - About - Disclaimer - Privacy